stockrowKiniksa Pharmaceuticals International, plc
KNSA Healthcare Drug Manufacturers Specialty & Generic
Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024.
- Revenue
- +58.1%
- EPS
- +142.2%
- Free cash flow
- +43.5%
Quarter to September 2026, against a year earlier
Follow KNSA
Alert me
Kiniksa Pharmaceuticals International, plc (KNSA) Return on equity
Kiniksa Pharmaceuticals International, plc's return on equity over the twelve months to 30 September 2026 was 17.6%, up 5.9 percentage points from fiscal 2025 (11.7%). Over the past ten years it has ranged from −108.9% (fiscal 2018) to 112.4% (fiscal 2017); the current reading is higher than 70% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of −0.80% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 11.7% | 21.58 |
| FY2024 | −9.85% | (13.22) |
| FY2023 | 3.37% | (59.73) |
| FY2022 | 63.1% | 126.65 |
| FY2021 | −63.6% | (3.49) |
| FY2020 | −60.1% | 4.09 |
| FY2019 | −64.2% | 44.76 |
| FY2018 | −108.9% | (221.30) |
| FY2017 | 112.4% | 70.86 |
| FY2016 | 41.5% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| LQDA Liquidia Corporation compare | 131.8% |
| LNTH Lantheus Holdings, Inc. compare | 21.8% |
| KNSA Kiniksa Pharmaceuticals International, plc | 17.6% |
| RDY Dr. Reddy's Laboratories Ltd compare | 6.60% |
| ALKS Alkermes plc compare | −0.02% |
| ELAN Elanco Animal Health Incorporated compare | −2.98% |
| HIMS Hims & Hers Health, Inc. compare | −32.0% |
| SUPN Indivior Pharmaceuticals Inc. compare | −337.8% |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | −53,107.2% |
| Drug Manufacturers Specialty & Generic industry median | −0.80% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on KNSA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement